Company
Intrabio
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
2
Originals and new uses
Phase 3 trials
3
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type CPivotal-lookingRecruiting
IntraBio IncIndustry
NCT05163288 · 53 participants (planned) · Start Jun 30, 2022 · Primary completion Jun 12, 2030
Drug: N-Acetyl-L-Leucine · For: Niemann-Pick Disease, Type C
Sites: Rochester, Minnesota; Parkville, Australia; Prague, Czechia · 14 sites in all
Marketed drugs (1)
Newest FDA action first.
- Aqneursa Levacetylleucine · 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.